{"id":"sucroferric-oxyhydroxide-chewable-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Discolored (dark) stools"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4802224","moleculeType":"Small molecule","molecularWeight":"88.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This iron-based phosphate binder works by forming insoluble complexes with dietary phosphate in the GI lumen, preventing phosphate absorption and lowering serum phosphate concentrations. It is particularly useful in dialysis patients and those with chronic kidney disease who need to control hyperphosphatemia. The chewable tablet formulation allows for flexible dosing and improved patient compliance.","oneSentence":"Sucroferric oxyhydroxide binds phosphate in the gastrointestinal tract to reduce serum phosphate levels in patients with chronic kidney disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:55.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperphosphatemia in patients with chronic kidney disease on dialysis"},{"name":"Hyperphosphatemia in patients with chronic kidney disease not on dialysis"}]},"trialDetails":[{"nctId":"NCT04485039","phase":"PHASE4","title":"Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2022-06-08","conditions":"Smallpox","enrollment":44},{"nctId":"NCT04046263","phase":"PHASE4","title":"Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-02-01","conditions":"Peritoneal Dialysis Complication, Hyperphosphatemia, Hypoalbuminemia","enrollment":17},{"nctId":"NCT03644264","phase":"PHASE3","title":"PA21 Safety and Efficacy in Adult Chinese Subjects","status":"COMPLETED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2018-08-31","conditions":"Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia","enrollment":286},{"nctId":"NCT02688764","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia","status":"TERMINATED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2016-05-26","conditions":"Hyperphosphatemia","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Velphoro"],"phase":"marketed","status":"active","brandName":"Sucroferric Oxyhydroxide Chewable Tablet","genericName":"Sucroferric Oxyhydroxide Chewable Tablet","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sucroferric oxyhydroxide is a small molecule that acts as a phosphate sequestering agent. It is used to treat conditions such as hyperphosphatemia and hypoalbuminemia in patients with chronic kidney disease requiring chronic dialysis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}